NCT02547766View on ClinicalTrials.gov

Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Heart Failure
Interventions
DRUG

Anakinra

Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.

Trial Locations (1)

84132

University of Utah, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT02547766 - Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices | Biotech Hunter | Biotech Hunter